The NICE Appraisal on donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl) will be the first to go through this process in the spring.As an interim measure, the Scottish Executive has asked Drugs and Therapeutics Committees to review any advice they may have provided to their clinicians on the use of these treatments in Alzheimer's disease, taking into account the NICE advice. S1W-12788